Compare SY & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SY | CRBP |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | China | United States |
| Employees | 2348 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 195.2M | 190.3M |
| IPO Year | 2018 | 2014 |
| Metric | SY | CRBP |
|---|---|---|
| Price | $2.04 | $3.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $7.34 | ★ $33.22 |
| AVG Volume (30 Days) | 186.3K | ★ 1.1M |
| Earning Date | 11-24-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.37% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | $34.60 | N/A |
| Revenue Next Year | $36.03 | $131.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $1.28 | $2.81 |
| 52 Week High | $3.90 | $12.88 |
| Indicator | SY | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 39.66 | 34.65 |
| Support Level | $1.91 | $2.81 |
| Resistance Level | $2.07 | $8.13 |
| Average True Range (ATR) | 0.11 | 0.43 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 30.24 | 39.54 |
So-Young International Inc is an aesthetic treatment platform in China connecting consumers with online services and offline treatments. Its online platform operates across multiple access points, including mobile app, Weixin mini program, and soyoung.com website, where both consumers and aesthetic practitioners can access media content, an engaging social community and a transparent reservation system. The company has four reportable segments: Aesthetic treatment services group, Platform service group, Wuhan Miracle, and Others. The majority of revenue is derived from the Platform service group, which generates revenue by providing information services and reservation services. All the company's revenues are derived from within the PRC.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.